Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-19T11:02:36.124Z Has data issue: false hasContentIssue false
  • English
  • Français

Current use of chemotheraphy for head and neck cacer

Published online by Cambridge University Press:  29 June 2007

Randall P. Morton
Randall P. Morton
Affiliation:
ENT Department, Green Lane Hospital, Green Lane, Auckland, 3, New Zealand.
Get access Rights & Permissions [Opens in a new window]

Summary

A postal survey of 100 members of the Association of Head and Neck Oncologists of Great Britain was conducted in the first 6 months of 1983. The sample consisted principally of Otolaryngologists (50 per cent), Radiotherapists (14 per cent), Medical Oncologists (10 per cent), Oral Surgeons (10 per cent) and Plastic Surgeons (10 per cent). More than 80 per cent of those who completed the questionnaire used chemotherapy for Head and Neck cancer (72 per cent used it for palliation, and 64 per cent as part of combined modality therapy). There was great variation in the chemotherapeutic regimens used by the various responders. Furthermore, most responders used more than one regimen. Methotrexate was the agent most frequently used. No specific regimen, either single-agent or multiple-agent, enjoyed universal acceptance, although the combination of Vincristine, Bleomycin and Methotrexate was popular. Chemotherapy was thought by most responders to have a useful but as yet undefined place in the management of Head and Neck cancer. This survey underlines the need for prospective, controlled, clinical trials into the efficacy of cytotoxic chemotherapy for Head and Neck cancer.

Type
Research Article
Information
The Journal of Laryngology & Otology , Volume 98 , Issue 8 , August 1984 , pp. 819 - 828
Copyright
Copyright © JLO (1984) Limited 1984

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bradley, P. J. and Morton, R. P. (1982) Head and Neck cancer. Lancet, ii: 1168–1169.CrossRefGoogle Scholar
Cachin, Y. (1982) Adjuvant chemotherapy in head and neck carcinoma. Clinical Otolaryngology, 7: 121–132.CrossRefGoogle ScholarPubMed
Clifford, P., O'Connor, A. D., Carter, R. L., et al. (1982) Combination treatment in advanced head and neck cancer. Lancet, ii: 708–709.CrossRefGoogle Scholar
Hong, W. K. and Bromer, R. (1983) Chemotherapy in head and neck cancer. New England Journal of Medicine, 308: 75–78.CrossRefGoogle ScholarPubMed
Mead, G. M., Macbeth, F. R., Green, J. A., et al. (1982) Treatment of head and neck cancer. Lancet, ii: 979.CrossRefGoogle Scholar
Morton, R. P. and Campbell, I. T. (1983) Nutritional support and cancer chemotherapy. Lancet ii: 687.CrossRefGoogle Scholar
Price, L. A. and Hill, B. T. (1977) A Kinetically-based logical approach to the chemotherapy of head and neck cancer. Clinical Otolaryngology, 2: 340–345.CrossRefGoogle Scholar
Price, L. A. and Hill, B. T. (1980) Effective combination chemotherapy for squamous cell carcinomas of the head and neck. Journal of Laryngology and Otology, 94: 89–90.CrossRefGoogle ScholarPubMed
Stell, P. M. (1982) Trials in head and neck cancer. Lancet, ii: 816.CrossRefGoogle Scholar
Stell, P. M., Strickland, P., Fraser, J. G., et al. (1983) Sequential chemotherapy and radiotherapy in advanced head and neck cancer. Clinical Radiology, 43: 464–467.Google Scholar
Sutton, M. (1982) Is palliative cytotoxic chemotherapy ever indicated? Lancet, i: 106.CrossRefGoogle Scholar
Tate, H. C., Rawlinson, J. B. and Freedman, L. S. (1979) Randomised comparative studies in the treatment of cancer in the United Kingdom: room for improvement? Lancet, ii: 623–625.CrossRefGoogle Scholar
Wrighton, R. J. (1979) Cancer chemotherapy. Journal of the Royal Society of Medicine, 72: 1–2.CrossRefGoogle ScholarPubMed